Sudeep Pharma Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 7,546,376 (50%) | — | ₹44,750 Cr |
| NII (HNI) | — | 2,263,912 (15%) | — | ₹13,425 Cr |
| Retail | — | 5,282,462 (35%) | — | ₹31,325 Cr |
| Σ Total | — | 15,092,750 (100%) | — | ₹895,000 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 25 | ₹14,825 |
| Retail (Max) | 13 | 325 | ₹192,725 |
| S-HNI (Min) | 14 | 350 | ₹207,550 |
| B-HNI (Min) | 67 | 1,675 | ₹993,275 |
Financial Statements Amount in ₹ Crore
| Metric | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 130 | 511 | 465 |
| EBITDA | 49 | 199 | 188 |
| Profit After Tax | 31 | 139 | 133 |
| Net Worth | 688 | 498 | 359 |
| Total Assets | 922 | 717 | 514 |
| Reserves & Surplus | 669 | 481 | 355 |
| Total Borrowing | 136 | 135 | 75 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I – 75.81
- General corporate purposes – 12.67
Company Overview
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.
The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium
The company supplies more than 200 products to a diverse customer base across pharma, food, and nutrition sectors
The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients.
Product Portfolio:
- Pharmaceutical, Food and Nutrition Business
- Specialty Ingredients Business
- Triturates
As of December 31, 2024, the company had 704 permanent employees.
Competitve Strengths:
- Market leadership with a diversified product portfolio in a high barrier industry
- Distinguished global customer base with long-standing relationships with key customers
- Well-equipped and regulatory compliant Manufacturing Facilities
- Strong research and development capabilities